{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T18:48:16Z","timestamp":1769971696122,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SGH - consultant for Incyte, Bristol Meyers Squibb, and Generon."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41409-022-01628-3","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:02:46Z","timestamp":1646474566000},"page":"790-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors and outcomes of flares in chronic graft-versus-host disease"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-4362","authenticated-orcid":false,"given":"Grigori","family":"Okoev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-0176","authenticated-orcid":false,"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3799","authenticated-orcid":false,"given":"Claudio G.","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-0852","authenticated-orcid":false,"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-0556","authenticated-orcid":false,"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bbmt.2011.03.006","volume":"17","author":"J Pidala","year":"2011","unstructured":"Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1528\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","volume":"24","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24:555\u201362.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2016","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Cheng G, Kerr H, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2016;21:389\u2013401.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1628_CR4","unstructured":"Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med.1997;16:901\u201310. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/%28SICI%291097-0258%2819970430%2916%3A8%3C901%3A%3AAID-SIM543%3E3.0.CO%3B2-M."},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RL Prentice","year":"1981","unstructured":"Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373\u20139.","journal-title":"Biometrika."},{"key":"1628_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187\u2013202.","journal-title":"J R Stat Soc Ser B."},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1017\/CBO9780511810725.016","volume":"1083","author":"PR Rosenbaum","year":"2006","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Matched Sampl Causal Eff. 2006;1083:170\u201384.","journal-title":"Matched Sampl Causal Eff"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"},{"key":"1628_CR10","doi-asserted-by":"crossref","unstructured":"Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501\u20136. http:\/\/ashpublications.org\/blood\/article-pdf\/104\/12\/3501\/1703629\/zh802304003501.pdf.","DOI":"10.1182\/blood-2004-01-0200"},{"key":"1628_CR11","doi-asserted-by":"crossref","unstructured":"Kim DH, Sohn SK, Baek JH, Lee KH, Lee JH, Choi SJ, et al. Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD. Bone Marrow Transplant. 2007;40:779\u201384. https:\/\/pubmed.ncbi.nlm.nih.gov\/17700602\/.","DOI":"10.1038\/sj.bmt.1705806"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01628-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:27:41Z","timestamp":1726777661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01628-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]},"assertion":[{"value":"9 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests, none of which is directly relevant to this work. BRB\u2014receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics; research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre biopharmaceuticals, Carisma Therapeutics, Inc., and is a co-founder of Tmunity Therapeutics. SGH\u2014consultant for Incyte, Bristol Meyers Squibb, and Generon. DJW\u2014research support from Incyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}